PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.

Recruiting

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: lorlatinib
Drug: crizotinib
Drug: brigatinib
Drug: ceritinib
Drug: alectinib
Drug: atezolizumab
Drug: bevacizumab
Drug: paclitaxel
Drug: carboplatin
Drug: docetaxel
Drug: erlotinib
Drug: gefitinib
Drug: afatinib
Drug: dacomitinib
Drug: osimertinib
Drug: pembrolizumab
Drug: nivolumab
Drug: entrectinib

First Posted Date: 2023-04-28

Last Posted Date: 2023-10-10

Lead Sponsor: Pfizer

Target Recruit Count: 20605

Registration Number: NCT05834348

Locations: 🇳🇴
Pfizer Norway, Oslo, Norway

A Study to Learn About a Type of Pneumococcal Vaccine With a New Ingredient (PF-07872411) Intended to Enhance the Effects of the Vaccine Which is Given to Adults

Phase 1

Completed

Conditions: Pneumococcal Disease

Interventions: Other: Low dose multivalent pneumococcal conjugate vaccine formulation A
Other: Low dose multivalent pneumococcal conjugate vaccine formulation B
Biological: Low dose of multivalent pneumococcal conjugate vaccine control
Biological: Standard dose multivalent pneumococcal conjugate vaccine control

First Posted Date: 2023-04-26

Last Posted Date: 2024-07-29

Lead Sponsor: Pfizer

Target Recruit Count: 90

Registration Number: NCT05831124

Locations: 🇺🇸
Centennial Medical Group, Elkridge, Maryland, United States
🇺🇸
Rochester Clinical Research, LLC, Rochester, New York, United States
🇺🇸
Indago Research & Health Center, Inc, Hialeah, Florida, United States

and more 5 locations

A Study to Learn About How Itraconazole Affects the Blood Level of Study Medicine (PF-07817883) in Healthy Adults.

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PF-07817883
Drug: Itraconazole

First Posted Date: 2023-04-20

Last Posted Date: 2024-10-04

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT05822440

Locations: 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States

Atrial Fibrillation Data Linkage Non-Interventional Study

Not yet recruiting

Conditions: Atrial Fibrillation

First Posted Date: 2023-04-12

Last Posted Date: 2024-10-22

Lead Sponsor: Pfizer

Target Recruit Count: 19388

Registration Number: NCT05810727

A Study to Learn About the Safety and Effects of Rimegepant to Prevent Migraine in Chinese Subjects.

Phase 3

Recruiting

Conditions: Migraine

Interventions: Drug: Rimegepant
Drug: Placebo

First Posted Date: 2023-04-12

Last Posted Date: 2024-11-13

Lead Sponsor: Pfizer

Target Recruit Count: 784

Registration Number: NCT05810038

Locations: 🇨🇳
Lanzhou university second hospital, Lanzhou, Gansu, China
🇨🇳
The Second People's hospital of Hefei, Hefei, Anhui, China
🇨🇳
Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China

and more 47 locations

A Study to Learn How Different Amounts of the Study Medicine Called PF-07328948 Are Tolerated and Act in the Body in Healthy Adults

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PF-07328948
Drug: Placebo

First Posted Date: 2023-04-11

Last Posted Date: 2024-07-19

Lead Sponsor: Pfizer

Target Recruit Count: 86

Registration Number: NCT05807490

Locations: 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States
🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium

To Understand the Safety and Effects of a C. Difficile Vaccine With New Adds-Ons That Will Be Given to Healthy Adults

Phase 2

Active, not recruiting

Conditions: Clostridoides Difficile Associated Disease

Interventions: Biological: C. difficile vaccine formulation 1.
Biological: C. difficile vaccine formulation 2.
Biological: C. difficile vaccine formulation 3.
Biological: C. difficile vaccine (previously studied formulation).
Other: Saline Placebo.

First Posted Date: 2023-04-10

Last Posted Date: 2024-11-21

Lead Sponsor: Pfizer

Target Recruit Count: 689

Registration Number: NCT05805826

Locations: 🇺🇸
HOPE Research Institute, Phoenix, Arizona, United States
🇺🇸
Hope Research Institute, Phoenix, Arizona, United States
🇺🇸
The Pain Center of Arizona, Phoenix, Arizona, United States

and more 21 locations

A Study to Understand the Effect and Safety of the Study Medicine PF-07817883 in Adults Who Have Symptoms of COVID-19 But Are Not Hospitalized

Phase 2

Completed

Conditions: SARS-CoV-2 Infection

Interventions: Drug: PF-07817883
Drug: Placebo

First Posted Date: 2023-04-05

Last Posted Date: 2024-10-09

Lead Sponsor: Pfizer

Target Recruit Count: 240

Registration Number: NCT05799495

Locations: 🇺🇸
Remington-Davis, Inc, Columbus, Ohio, United States
🇺🇸
Proactive Clinical Research LLC, Edinburg, Texas, United States
🇺🇸
Franco Felizarta, Md, Bakersfield, California, United States

and more 48 locations

Treatment Patterns Among Patients With Venous Thromboembolism in the United States

Completed

Conditions: Venous Thromboembolism

Interventions: Drug: warfarin
Drug: apixaban

First Posted Date: 2023-04-03

Last Posted Date: 2024-11-22

Lead Sponsor: Pfizer

Target Recruit Count: 13945

Registration Number: NCT05795062

Locations: 🇺🇸
Pfizer, New York, New York, United States

A Study To Learn About The Effects Of Pneumococcal Vaccine In People With HIV

Completed

Conditions: HIV
Pneumonia
Infections, Pneumococcal

Interventions: Biological: Vaccine Administration

First Posted Date: 2023-04-03

Last Posted Date: 2024-11-01

Lead Sponsor: Pfizer

Target Recruit Count: 1

Registration Number: NCT05794191

Locations: 🇺🇸
Pfizer, New York, New York, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy